Expert Commentary

Ideal patient selection for this new approach to HT

OBG Manag. 2014 October;26(10)
By
Anne Moore, DNP, APN

A peer-to-peer audiocast with JoAnn Pinkerton, MD, and Anne Moore, DNP, APN

 

Dr. Moore and Dr. Pinkerton focus on a new estrogen therapy: the combination conjugated estrogen and bazedoxifene (CE/BZA) for the treatment of moderate to severe hot flashes due to menopause and the prevention of menopausal osteoporosis.

Which patients can benefit most? What is CE/BZA’s safety profile? How do traditional estrogen-progestin therapies compare with CE/BZA therapy? Tune in for answers to these questions and more.

Read Cases in Menopause: Conjugated estrogen plus bazedoxifene —a new approach to estrogen therapy, from Dr. Anne Moore and Dr. JoAnn Pinkerton (October 2014).

Recommended Reading

New agent builds bone bigger, faster
MDedge ObGyn
Early low-dose menopausal hormone therapy did not affect atherosclerosis
MDedge ObGyn
Laparoscopic myomectomy with enclosed transvaginal tissue extraction
MDedge ObGyn
Vaginal bowel control device shown safe, effective in pivotal trial
MDedge ObGyn
Laparoscopic dual-port contained power morcellation: An offered solution
MDedge ObGyn
Estrogen does not cause breast cancer
MDedge ObGyn
2014 Update on sexual dysfunction
MDedge ObGyn
After 3-year stumble, new weight-loss drug wins FDA approval
MDedge ObGyn
Conjugated estrogen plus bazedoxifene—a new approach to estrogen therapy
MDedge ObGyn
New mobile app assists clinicians in assessing menopausal patients
MDedge ObGyn

Related Articles